Progressive multifocal leukoencephalopathy (PML): management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Progressive multifocal leukoencephalopathy (PML): management. Serum anti JC virus antibody. Fully referenced neurology checklist.
Pre-Natalizumab assessments
- Serum anti JC virus antibody
- Magnetic resonance imaging (MRI)
- Urine JC virus DNA polymerase chain reaction (PCR)
PML monitoring on Natalizumab therapy
Locked: subscribe to see this section.
Treatment guidelines in suspected PML
Locked: subscribe to see this section.
Treatment of PML
Locked: subscribe to see this section.
Re-starting treatment in suspected PML
Locked: subscribe to see this section.
Investigational treatments
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012; 12:25-35.
- Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
- Warnke C, Menge T, Hartung H-P, et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol 2010; 67:923-930.
- Sorenson PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients rated with natalizumab. Mult Scler 2012; 18:143-152.
- McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. JNNP 2016; 87:117-125.
- And 12 more. Subscribe to see the full list
